<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02658448</url>
  </required_header>
  <id_info>
    <org_study_id>G201001</org_study_id>
    <nct_id>NCT02658448</nct_id>
  </id_info>
  <brief_title>GTx-024 as a Treatment for Stress Urinary Incontinence in Women</brief_title>
  <official_title>GTx-024 as a Treatment for Stress Urinary Incontinence in Women: A Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GTx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GTx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether GTx-024 is safe and effective in the
      treatment of stress urinary incontinence in postmenopausal women.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of stress incontinence episodes/day.</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the effect of 12 weeks of treatment of GTx-024 on the number of stress incontinence episodes/day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stress urinary incontinence as assessed by 24 hour pad weight test</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the effect of 12 weeks of treatment of GTx-024 on SUI as assessed by 24 hour pad weight test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress urinary incontinence as assessed by the Bladder Stress Test</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the effect of 12 weeks of treatment of GTx-024 on SUI as assessed by the Bladder Stress Test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MESA Urinary Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the effect of 12 weeks of treatment of GTx-024 on patient reported stress urinary incontinence symptoms as assessed by the MESA Urinary Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Severity Scale (PGI-S)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the effect of 12 weeks of treatment of GTx-024 on patient reported impression of stress urinary incontinence severity as assessed by the Patient Global Impression of Severity Scale (PGI-S)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement Scale (PGI-I)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the effect of 12 weeks of treatment of GTx-024 on patient reported impression of improvement as assessed by the Patient Global Impression of Improvement Scale (PGI-I).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Distress Inventory Questionnaire (UDI-6)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the effect of 12 weeks of treatment of GTx-024 on patient reported urogenital distress as assessed by the Urinary Distress Inventory Questionnaire (UDI-6).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence Impact Questionnaire (IIQ-7)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the effect of 12 weeks of treatment of GTx-024 on patient reported impact of urinary incontinence on daily life as assessed by the Incontinence Impact Questionnaire (IIQ-7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Female Sexual Function Index Questionnaire (FSFI)</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the effect of 12 weeks of treatment of GTx-024 on patient reported sexual function as indicated on the completion of the Female Sexual Function Index Questionnaire (FSFI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pelvic floor muscles as assessed by MRI, in patients where a MRI is not contraindicated</measure>
    <time_frame>12 weeks</time_frame>
    <description>Quantitative assessments may include the area of the levator ani , the anteroposterior and transverse diameters, and/or other relevant parameters.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of voids/day</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the effect of 12 weeks of treatment of GTx-024 on the number of voids/day</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>To describe the safety profile of GTx-024 3 mg PO daily in subjects with stress urinary incontinence.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>GTx-024 3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GTx-024 softgel capsules will be administered once daily to a total dose of 3 mg for up to 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GTx-024</intervention_name>
    <description>GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg</description>
    <arm_group_label>GTx-024 3 mg</arm_group_label>
    <other_name>enobosarm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Give voluntary, written and signed, informed consent

          -  Female

          -  Age18 to 80 years old be clinically confirmed as postmenopausal. Subjects must have
             undergone the onset of spontaneous, medically induced or surgical menopause prior to
             the start of this study. Spontaneous menopause is defined as 12 months of spontaneous
             amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels &gt; 40 mIU/ml or
             6 weeks postsurgical bilateral oophorectomy with or without hysterectomy

          -  SUI symptoms for at least 6 months duration

          -  Predominant SUI (MESA questionnaire)

          -  24 hour pad weight &gt;3 gms at baseline

          -  A minimum of 1 SUI episode per day, in the 3 day diary

          -  3-15 SUI episodes per day, averaged over 3 days, in the 3 day diary

          -  Serum AST and ALT within normal limits

          -  Total bilirubin within normal limits

          -  Positive Bladder Stress Test during screening

          -  Subject agrees to not start any new treatment (medication or otherwise) that is known
             to affect lower urinary tract function throughout the treatment and follow up periods

          -  Subject agrees to maintain on a stable dose of any medication known to affect lower
             urinary tract function, including but not limited to anticholinergics, tricyclic
             antidepressants, or alpha-adrenergic blockers, throughout the treatment and follow-up
             period

        Exclusion Criteria:

          -  Pelvic floor physical therapy in a clinical setting within 30 days prior to screening

          -  History of pelvic radiation treatment

          -  History of urethral diverticula

          -  History of urethral sling, anterior prolapse repair, ureteral bulking agents and/or
             other SUI procedure or surgery

          -  Known vesicoureteral reflux, vaginal prolapse beyond the introitus, or other
             significant urological findings, including pelvic floor abnormalities which, in the
             judgement of the investigator, could impact treatment

          -  Urinary incontinence of neurogenic etilogy

          -  Patient is morbidly obese (defined as 100 pounds over their ideal body weight, or body
             mass index 40 or greater)

          -  Chronic hepatitis

          -  Hepatic cirrhosis

          -  HIV and/or hepatitis A, B, or C

          -  Subjects taking systemic hormone products

          -  Subjects with a history of breast or endometrial cancer

          -  Myocardial infarction or arterial thromboembolic events within 6 months prior to
             Baseline, severe or unstable angina, New York Heart Association (NYHA) Class III or IV
             disease, serious uncontrolled cardiac arrhythmia grade II or higher according to NYHA,
             uncontrolled hypertension (systolic &gt; 150 and/or diastolic &gt; 100 mm Hg)

          -  Subjects with an entry measurement of &gt; 5 mm endometrial stripe thickness

          -  Clinically confirmed urinary tract infection

          -  Any other condition which per investigators' judgment may increase subject risk
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth M. Peters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urologic Consultants of Southeastern Pennsylvania</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn Center for Continence and Pelvic Health, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2016</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

